US Fertility Company Profile

Background

US Fertility is the largest physician-owned and physician-led partnership of top-tier fertility practices in the United States. Formed in 2020 through a collaboration between Amulet Capital Partners and Shady Grove Fertility, US Fertility unites leading fertility centers to enhance patient care through shared expertise and innovative practices. The organization's mission is to deliver the joy of parenthood through advanced reproductive medicine and innovative science. To date, US Fertility and its affiliated practices have assisted over 225,000 individuals and couples in building their families using assisted reproductive technology.

Key Strategic Focus

US Fertility's strategic focus centers on providing comprehensive, patient-centered fertility care by leveraging collective expertise and driving innovation. The organization specializes in assisted reproductive technologies (ART), including in vitro fertilization (IVF), egg donation, and fertility preservation. By offering advanced business and digital solutions, US Fertility streamlines and enhances the delivery of exceptional patient care across its extensive network of over 100 clinic locations and 32 IVF laboratories.

Financials and Funding

In 2020, US Fertility was established through a partnership between Amulet Capital Partners, a middle-market private equity investment firm focused exclusively on the healthcare sector, and Shady Grove Fertility, the largest independent fertility practice in the U.S. This collaboration aimed to create a robust platform offering technical and administrative support to affiliated practices, thereby enhancing operational efficiency and patient outcomes.

Pipeline Development

US Fertility continuously expands its services and geographic reach. In January 2022, the organization welcomed the Center of Reproductive Medicine (CORM) into its network, extending the Shady Grove Fertility brand into Houston, Texas. This partnership reflects US Fertility's commitment to broadening access to high-quality reproductive healthcare services.

Technological Platform and Innovation

US Fertility distinguishes itself through the integration of advanced technological platforms and innovative practices:

Research Division: Conducts and publishes high-quality studies to advance reproductive medicine, aiming to provide more effective care to infertility patients.

Innovation Fund: Invests strategically in early-stage ventures with the potential to improve access to care and pregnancy outcomes in the fertility field.

Academic Programs: Focuses on training the next generation of physicians and embryologists, ensuring continuous advancement in clinical excellence.

These initiatives underscore US Fertility's dedication to innovation and excellence in reproductive healthcare.

Leadership Team

US Fertility's leadership comprises experienced professionals committed to advancing reproductive healthcare:

Richard Jennings: Chief Executive Officer since January 2023. Previously served as CEO of Generate Life Sciences, overseeing operations of brands like California Cryobank and Donor Egg Bank. Holds a Bachelor of Science in Chemical Engineering and an MBA from Harvard Business School.

Joshua Saipe: Chief Financial Officer.

Jaime Shamonki, M.D.: Chief Operating Officer.

Ethan Harris: Chief Information Officer.

Danny Charles: Chief Development Officer.

Vicki Gerber: Executive Vice President, Operations.

Kirstin Runa: Executive Vice President, Operations.

Danielle Soltesz: Executive Vice President, Operations.

Judah Shechter: General Counsel.

The clinical and scientific leadership includes:

Kate Devine, M.D.: Medical Director and Chief Research Officer.

Anish A. Shah, M.D., M.H.S.: Executive Growth Physician.

Eduardo Hariton, M.D., MBA: VP, Strategic Initiatives and Managing Director, USF Innovation Fund.

Benjamin S. Harris, M.D., M.P.H.: Executive Physician for Diversity, Equity, and Inclusion.

Lucky Sekhon, M.D.: Executive Marketing Physician.

Matthew “Tex” VerMilyea, Ph.D., HCLD/CC: Vice President of Scientific Advancement.

Jim Graham, M.S.: VP, Laboratory Operations.

This team exemplifies US Fertility's commitment to excellence, patient focus, integrity, compassion, and commitment.

Leadership Changes

In September 2022, US Fertility announced that Richard Jennings would join the Board of Directors and assume the role of CEO effective January 1, 2023. He succeeded Mark Segal, who transitioned to Chairman of the Board after 25 years as CEO.

Competitor Profile

Market Insights and Dynamics

The U.S. fertility market is experiencing significant growth, driven by factors such as increasing infertility rates, delayed childbearing, and advancements in reproductive technologies. The market size was valued at approximately USD 9.00 billion in 2025 and is projected to reach USD 19.72 billion by 2034, growing at a CAGR of 9.10%.

Competitor Analysis

Key competitors in the fertility services sector include:

Prelude Fertility: A network of fertility clinics offering services such as IVF, egg donation, and egg freezing. Founded in 2016, Prelude has expanded through acquisitions and partnerships, becoming a significant player in the U.S. fertility market.

Boston IVF: A leading fertility clinic providing a range of ART services, known for its research and high success rates.

RMA Network (Reproductive Medicine Associates): Offers comprehensive fertility services with a focus on personalized care and advanced technologies.

INVO Bioscience: Developed the INVOcell device, offering a cost-effective and natural approach to IVF by allowing fertilization and early embryo development to occur within the woman's body.

These competitors focus on various aspects of fertility care, including technological innovation, patient-centered services, and expanding access to treatments.

Strategic Collaborations and Partnerships

US Fertility has engaged in strategic partnerships to enhance its services and reach:

Center of Reproductive Medicine (CORM): In January 2022, CORM joined the US Fertility network, adopting the Shady Grove Fertility brand and extending services into Houston, Texas.

Alife Health: In November 2024, US Fertility partnered with Alife Health to pilot AI tools in embryology laboratories, aiming to enrich embryo cataloging and provide advanced insights into laboratory operations.

These collaborations reflect US Fertility's commitment to innovation and expanding access to high-quality reproductive healthcare.

Operational Insights

US Fertility's operational strategy focuses on integrating advanced business and digital solutions to streamline administrative functions, allowing physicians to concentrate on patient care. By leveraging collective expertise and best practices across its network, US Fertility enhances treatment outcomes and patient experiences. The organization's physician-owned and physician-led model fosters alignment between clinical and administrative operations, contributing to its competitive advantage in the fertility services market.

Strategic Opportunities and Future Directions

Looking ahead, US Fertility aims to:

Expand Geographic Reach: Continue growing its network by partnering with leading fertility practices in new regions to increase access to reproductive healthcare.

Invest in Innovation: Further develop and implement cutting-edge technologies and research initiatives to improve treatment outcomes and patient experiences.

Enhance Patient-Centered Care: Focus on personalized treatment plans and support services to meet the diverse needs of individuals and couples seeking fertility assistance.

By capitalizing on its strengths and strategic initiatives, US Fertility is well-positioned to lead advancements in reproductive medicine and support the growing demand for fertility services.

Contact Information

For more information, visit the official website: US Fertility

US Fertility maintains a presence on various social media platforms to engage with patients and the broader community.